Literature DB >> 25684038

The Association of Serum Galectin-3 Levels with Atrial Electrical and Structural Remodeling.

Muhammed U Yalcin1, Kadri M Gurses2, Duygu Kocyigit2, Hande Canpinar3, Ugur Canpolat4, Banu Evranos2, Hikmet Yorgun2, Mehmet L Sahiner2, Ergun B Kaya2, Tuncay Hazirolan5, Lale Tokgozoglu2, Mehmet A Oto2, Necla Ozer2, Dicle Guc3, Kudret Aytemir2.   

Abstract

INTRODUCTION: Left atrial (LA) interstitial fibrosis is known to have a role in the initiation and maintenance of atrial fibrillation (AF). The role of galectin-3 in the pathogenesis of cardiac fibrosis has been demonstrated in previous studies. We aimed to determine whether serum galectin-3 level is associated with markers of atrial remodeling, including the extent of LA fibrosis detected by delayed enhancement magnetic resonance imaging (DE-MRI) and atrial electromechanical delay (AEMD) in paroxysmal AF patients with preserved left ventricular (LV) functions. METHODS AND
RESULTS: Thirty-three patients (58 [28-74] years, 51.5% male) with paroxysmal AF who underwent DE-MRI prior to cryoballoon-based AF ablation were included in the study. Serum galectin-3 levels were measured with ELISA. LA volume index (B ± SE: 0.424 ± 0.504, 95% CI: 0.560-2.627, P = 0.004) and serum galectin-3 levels (B ± SE: 0.549 ± 7.745, 95% CI: 16.874-47.550, P < 0.001) were found to be independently correlated with extent of LA fibrosis detected with DE-MRI in paroxysmal AF patients with preserved LV function. Correlation analysis between AEMD parameters and baseline characteristics showed that galectin-3 was significantly correlated with intra-left (ρ = 0.432, P = 0.012) and inter-AEMD (ρ = 0.395, P = 0.023). Duration of AF, LAD, and extent of LA fibrosis were also found to be significantly correlated with AEMD parameters.
CONCLUSION: This is a hypothesis-generating study pointing out that serum galectin-3 level is significantly associated with atrial remodeling in paroxysmal AF patients with preserved LV function. Further studies are necessary to provide exact pathophysiological mechanisms.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial electromechanical delay; atrial fibrillation; atrial fibrosis; delayed-enhancement magnetic resonance imaging; galectin-3; remodeling

Mesh:

Substances:

Year:  2015        PMID: 25684038     DOI: 10.1111/jce.12637

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  23 in total

1.  sST2 and Galectin-3 genotyping in patients with persistent atrial fibrillation.

Authors:  Ruth Saez-Maleta; Ana Merino-Merino; Simon Gundin-Menendez; Ricardo Salgado-Aranda; Daniel AlKassam-Martinez; Virginia Pascual-Tejerina; Javier Martin-Gonzalez; Javier Garcia-Fernandez; Jose-Angel Perez-Rivera
Journal:  Mol Biol Rep       Date:  2021-01-23       Impact factor: 2.316

Review 2.  Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Falco Kosich; Katja Schumacher; Tatjana Potpara; Gregory Y Lip; Gerhard Hindricks; Jelena Kornej
Journal:  Clin Cardiol       Date:  2019-01-14       Impact factor: 2.882

3.  Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation.

Authors:  Duygu Kocyigit; Kadri Murat Gurses; Muhammed Ulvi Yalcin; Hande Canpinar; Ugur Canpolat; Banu Evranos; Hikmet Yorgun; Necla Ozer; Dicle Guc; Kudret Aytemir
Journal:  J Clin Lab Anal       Date:  2017-03-13       Impact factor: 2.352

4.  Risk factors for recurrence of atrial fibrillation.

Authors:  Antoniya Kisheva; Yoto Yotov
Journal:  Anatol J Cardiol       Date:  2021-05       Impact factor: 1.596

5.  The predictive value of galectin-3 levels on left atrial low voltage areas assessed by high-density mapping in patients with paroxysmal atrial fibrillation.

Authors:  Gökhan Aksan; Ahmet Yanık; Osman Can Yontar; Faruk Boyacı; Melisa Uçar; Mustafa Kürşat Şahin; Korhan Soylu
Journal:  J Arrhythm       Date:  2022-04-01

Review 6.  Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update.

Authors:  Alejandra Gutierrez; David R Van Wagoner
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

7.  Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Nisha Bansal; Leila R Zelnick; Elsayed Z Soliman; Amanda Anderson; Robert Christenson; Christopher DeFilippi; Rajat Deo; Harold I Feldman; Jiang He; Bonnie Ky; John Kusek; James Lash; Stephen Seliger; Tariq Shafi; Myles Wolf; Alan S Go; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2020-12-09       Impact factor: 11.072

8.  Electrocardiographic and Echocardiographic predictors of paroxysmal atrial fibrillation detected after ischemic stroke.

Authors:  Maria A Baturova; Seth H Sheldon; Jonas Carlson; Peter A Brady; Grace Lin; Alejandro A Rabinstein; Paul A Friedman; Pyotr G Platonov
Journal:  BMC Cardiovasc Disord       Date:  2016-11-03       Impact factor: 2.298

9.  Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation.

Authors:  Diana Hernández-Romero; Juan Antonio Vílchez; Álvaro Lahoz; Ana I Romero-Aniorte; Eva Jover; Arcadio García-Alberola; Rubén Jara-Rubio; Carlos M Martínez; Mariano Valdés; Francisco Marín
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

10.  Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation.

Authors:  Nicolas Clementy; Nazih Benhenda; Eric Piver; Bertrand Pierre; Anne Bernard; Laurent Fauchier; Jean-Christophe Pages; Dominique Babuty
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.